MIRA PHARMACEUTICALS INC (MIRA)

US60458C1045 - Common Stock

1.26  +0.11 (+9.57%)

After market: 1.2499 -0.01 (-0.8%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MIRA. MIRA was compared to 192 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for MIRA as it has an excellent financial health rating, but there are worries on the profitability. MIRA does not seem to be growing, but still is valued expensively.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MIRA has reported negative net income.
In the past year MIRA has reported a negative cash flow from operations.

1.2 Ratios

MIRA has a Return On Assets of -263.45%. This is amonst the worse of the industry: MIRA underperforms 92.93% of its industry peers.
With a Return On Equity value of -314.53%, MIRA is not doing good in the industry: 76.09% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -263.45%
ROE -314.53%
ROIC N/A
ROA(3y)-376.79%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

MIRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for MIRA has been increased compared to 1 year ago.
There is no outstanding debt for MIRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 3.61 indicates that MIRA is not in any danger for bankruptcy at the moment.
The Altman-Z score of MIRA (3.61) is better than 75.54% of its industry peers.
There is no outstanding debt for MIRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.61
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 6.11 indicates that MIRA has no problem at all paying its short term obligations.
MIRA has a better Current ratio (6.11) than 71.20% of its industry peers.
A Quick Ratio of 6.11 indicates that MIRA has no problem at all paying its short term obligations.
MIRA has a better Quick ratio (6.11) than 72.83% of its industry peers.
Industry RankSector Rank
Current Ratio 6.11
Quick Ratio 6.11

More info and screens

1

3. Growth

3.1 Past

MIRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.66%, which is quite impressive.
EPS 1Y (TTM)20.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, MIRA will show a small growth in Earnings Per Share. The EPS will grow by 6.44% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y17.65%
EPS Next 2Y13.11%
EPS Next 3Y6.44%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MIRA. In the last year negative earnings were reported.
Also next year MIRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.11%
EPS Next 3Y6.44%

More info and screens

0

5. Dividend

5.1 Amount

MIRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MIRA PHARMACEUTICALS INC

NASDAQ:MIRA (1/3/2025, 8:00:01 PM)

After market: 1.2499 -0.01 (-0.8%)

1.26

+0.11 (+9.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners4.81%
Inst Owner Change0%
Ins Owners7.87%
Ins Owner Change0%
Market Cap20.87M
Analysts82.5
Price Target12.33 (878.57%)
Short Float %5.13%
Short Ratio0.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.8%
Min EPS beat(2)-7.84%
Max EPS beat(2)11.45%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-13.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.84
P/tB 5.84
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0
BVpS0.22
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -263.45%
ROE -314.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-376.79%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.11
Quick Ratio 6.11
Altman-Z 3.61
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
EPS Next Y17.65%
EPS Next 2Y13.11%
EPS Next 3Y6.44%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.83%
EBIT Next 3Y305.86%
EBIT Next 5YN/A
FCF growth 1Y19.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.13%
OCF growth 3YN/A
OCF growth 5YN/A